Lack of association of CYP1A2-164 A/C polymorphism with breast cancer susceptibility: a meta-analysis involving 17,600 subjects.
Published data on the association between cytochrome P-450 1A2 (CYP1A2)-164 A/C polymorphism and breast cancer risk are inconclusive. To derive a more precise estimation of the relationship, a meta-analysis was performed. Medline, PubMed, Embase, and Web of Science were searched. Crude ORs with 95% CIs were used to assess the strength of association between CYP1A2-164 A/C polymorphism and breast cancer risk. The pooled ORs were performed for co-dominant model (AC versus AA, CC versus AA), dominant model (CC + AC versus AA), and recessive model (CC versus AA + AC), respectively. A total of 9 studies including 7,580 cases and 10,020 controls were involved in this meta-analysis. Overall, no significantly elevated breast cancer risk was found in all genetic models when all studies were pooled into the meta-analysis (AC versus AA: OR = 1.02, 95% CI = 0.92-1.13; CC versus AA: OR = 1.17, 95% CI = 0.83-1.64; dominant model: OR = 1.07, 95% CI = 0.93-1.23; and recessive model: OR = 1.13, 95% CI = 0.82-1.55). In the subgroup analysis by ethnicity or source of controls, there was still no significant association detected in all genetic models. In conclusion, upto date, there is still not enough evidence to indicate the association of CYP1A2-164 A/C polymorphism and breast cancer development.
Qiu
Li-Xin
LX
Department of Medical Oncology, Cancer Hospital, Fudan University, Shanghai, China.
Yao
Lei
L
Mao
Chen
C
Yu
Ke-Da
KD
Zhan
Ping
P
Chen
Bo
B
Yuan
Hui
H
Zhang
Jian
J
Xue
Kai
K
Hu
Xi-Chun
XC
D001943:Breast Neoplasms / Q000201:enzymology / Q000235:genetics*; D016022:Case-Control Studies; D019388:Cytochrome P-450 CYP1A2 / Q000235:genetics*; D005260:Female; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D006801:Humans; D016017:Odds Ratio; D010641:Phenotype; D011110:Polymorphism, Genetic; D018570:Risk Assessment; D012307:Risk Factors
C504573:CYP1A2 protein, human; D019388:Cytochrome P-450 CYP1A2